



Combination Therapy With Perindopril Plus Amlodipine Promising in Hypertension

Written by Emma Hitt Nichols, PhD

Combination therapy of hypertension with perindopril and amlodipine resulted in a larger decrease in blood pressure (BP) compared with monotherapy with either agent or placebo. Stéphane Laurent, MD, PhD, Hospital Européen Georges Pompidou, Paris, France, presented data from a clinical trial evaluating fixed-dose combination of perindopril and amlodipine in patients with hypertension.

Many patients have uncontrolled hypertension even when taking combination therapy of current antihypertensive agents. Current treatment guidelines recommend the use of fixed combinations of antihypertensive therapies early in the disease course. The purpose of this trial was to evaluate a new generation of antihypertensive combination therapy with optimized doses for the first-line use in patients newly diagnosed with hypertension.

The primary end points included superiority of perindopril (3.5 mg) plus amlodipine (2.5 mg) compared with placebo and monotherapy and noninferiority of perindopril (3.5 mg) plus amlodipine (2.5 mg) compared with perindopril (5 mg) and amlodipine (5 mg). The secondary end points included the response rate and safety profile of combination therapy.

In the double-blind study, 1497 patients with hypertension were randomly assigned to receive perindopril monotherapy of 3.5 or 5 mg, amlodipine monotherapy of 2.5 or 5 mg, perindopril (3.5 mg) plus amlodipine (2.5 mg), or placebo for about 8 weeks. All patients received placebo during the 2- to 3-week run-in period. At baseline, the mean age was 51.7 years; 46.7% of patients were men; mean body mass index was 26.8 kg/m²; mean weight was 77.7 kg; and mean abdominal waist circumference was 90.8 cm. In addition, 26.4% of patients were smokers; 26% consumed alcohol; 6.4% had hypercholesterolemia; 5.9% had dyslipidemia; and 15% had metabolic syndrome.

The study met all the primary end points ($p < 0.001$). Change in supine systolic BP from baseline was greatest in the perindopril + amlodipine arm (-22.0 mm Hg) and the amlodipine (5 mg) monotherapy arm (-21.8 mm Hg). The placebo (-14.2 mm Hg), perindopril (3.5 mg) monotherapy (-16.3 mm Hg), amlodipine (2.5 mg) monotherapy (-16.0 mm Hg), and perindopril (5 mg) monotherapy (-18.2 mm Hg) arms also showed a decrease in systolic BP from baseline. There was a similar trend for diastolic

BP. In the combination therapy arm, 43.5% of patients experienced normalization, compared with 37.9%, 33.3%, and 26.6% in the amlodipine (5 mg), perindopril (5 mg), and placebo arms ($p < 0.001$), respectively.

A greater rate of lower limb edema was noted in patients who received amlodipine (5 mg) monotherapy compared with perindopril monotherapy or combination therapy. In contrast, cough and orthostatic hypotension occurred more frequently in the perindopril monotherapy arm compared with the amlodipine monotherapy and combination therapy arms.

Dr. Laurent stated that data from this trial indicate that perindopril (3.5 mg) + amlodipine (2.5 mg) combination therapy provides a better benefit-risk ratio compared with monotherapy, as the combination resulted in a greater reduction in BP with a similar safety profile. Therefore, he suggested that combination therapy of hypertension with perindopril (3.5 mg) plus amlodipine (2.5 mg) may be suitable as first-line therapy.

Dietary Nitrate Improves BP

Written by Toni Rizzo

Mammals are unable to metabolize nitrate, but symbiotic bacteria on the dorsal tongue surface reduce dietary nitrate to nitrite, which is then converted to the potent vasodilator nitric oxide [Duncan C et al. *Nat Med* 1995]. Vikas Kapil, MD, PhD, William Harvey Research Institute, Queen Mary University, London, United Kingdom, presented results of The Chronic Effects of Beetroot Juice in Hypertensive Subjects study, which assessed whether a once-daily ingestion of dietary nitrate would exert a sustained effect on blood pressure (BP) in hypertensive patients [NCT01405898].

A total of 68 patients with stage 1 hypertension were enrolled in this randomized, double-blind, placebo-controlled trial. The patients were stratified according to whether they were treatment naive or previously treated (not to target) for hypertension. Following a 2-week run-in period, the patients were randomized to a dietary supplement consisting of 250 mL/day of beetroot juice containing dietary nitrate ($n=34$) or to placebo consisting of nitrate-free beetroot juice ($n=34$) for 4 weeks.

The primary endpoint was change in clinic, ambulatory, and home BP. The secondary endpoints were pulse-wave velocity (PWV), endothelial function assessed by measurement of flow-mediated dilatation, and plasma nitrite and nitrate concentrations. Clinic BP was measured 3 times every 15 minutes for 1 hour. The second and third readings at each time point were averaged overall. Ambulatory BP was measured once

every 20 minutes during the day and every 60 minutes during the night. Home BP was measured daily, in triplicate, with the second and third readings averaged.

Baseline characteristics were similar between the 2 treatment groups. Two patients in each arm dropped out of the study. Ingestion of dietary nitrate increased plasma nitrite by a mean \pm SD of 0.52 ± 0.37 mmol/L compared with a decrease of 0.01 ± 0.16 mmol/L after ingestion of placebo ($p < 0.001$). Plasma nitrate was also significantly increased after ingestion of dietary nitrate, as shown by an increase in plasma cyclic guanosine monophosphate of 2.52 ± 3.30 compared with a decrease of 0.91 ± 2.80 after ingestion of placebo.

Clinic systolic BP was significantly reduced by 8.7 ± 8.2 mm Hg after ingestion of nitrate compared with a reduction of 1.0 ± 8.4 mm Hg after ingestion of placebo ($p < 0.001$). Clinic diastolic BP was significantly reduced by 3.2 ± 5.4 mm Hg after ingestion of nitrate compared with a reduction of 0.7 ± 4.2 mm Hg after ingestion of placebo ($p < 0.050$).

Ambulatory systolic BP was significantly reduced by 6.6 ± 6.5 mm Hg after ingestion of nitrate compared with an increase of 0.8 ± 4.9 after ingestion of placebo ($p < 0.001$). Ambulatory diastolic BP was significantly reduced by 4.3 ± 6.0 mm Hg after ingestion of nitrate compared with an increase of 0.9 ± 3.8 mm Hg after ingestion of placebo ($p < 0.001$). Patients in the dietary nitrate group versus those in the placebo group had significant reductions in home systolic ($p = 0.001$) and diastolic ($p = 0.036$) BP.

Ingestion of dietary nitrate versus placebo significantly improved PWV ($+0.59 \pm 0.93$ vs $+0.01 \pm 1.11$ m/s, $p = 0.031$) and vessel dilatation ($+0.9 \pm 1.3\%$ vs $+0.1 \pm 0.6\%$, $p = 0.005$).

In this study, dietary nitrate lowered systolic and diastolic BP by about 8 and 4 mm Hg, respectively, improved endothelial function, and reduced arterial stiffness in hypertensive patients. According to Dr. Kapil, these results highlight the therapeutic potential of a high-nitrate diet for the prevention and treatment of hypertension. The results might also explain in part the cardioprotective effects of a fruit and vegetable rich diet.

Evidence-Based Highlights With Peer-Reviewed Integrity

MD Conference Express fills the gap between live presentation and publication in the academic literature by applying rigorous scientific review to our medical conference highlights reports.



OUR 5-STEP PEER-REVIEW PROCESS

- 1 Scientific committee guides topic selection
- 2 Data-driven content referenced against primary sources
- 3 Faculty confirm data and/or provide post-conference updates
- 4 Independent peer-review ensures accuracy and fair balance
- 5 Editors finalize publication

A publication of
The Goodwin Group
Connecting the World of Medicine

+1-617-370-8088
www.goodwingroupintl.com
reports@goodwingroupintl.com
www.mdconferenceexpress.com

visit us, like us, and tweet

MD CONFERENCE EXPRESS



Click to like us on Facebook
facebook/mdconferenceexpress